Risk factors for acute postoperative intraocular pressure elevation after phacoemulsification in glaucoma patients

AsianOphthalmology Alliance logo Risk factors for acute postoperative intraocular pressure elevation after phacoemulsification in glaucoma patients

Author(s): Slabaugh M, Bojikian K, Moore D, Chen P
Treatments discussed: acetazolamide

PURPOSE To evaluate the risk factors for and frequency of an acute intraocular pressure (IOP) elevation (spike) after phacoemulsification in patients with glaucoma.

(more…) (2720)

FDA accepts Regeneron’s Eylea sBLA for standard review

AsianOphthalmology Alliance logo FDA accepts Regeneron’s Eylea sBLA for standard review

The supplemental Biologics License Application (sBLA) on Eylea intravitreal injection (aflibercept, Regeneron, Tarrytown, N.Y.) for the treatment of diabetic macular edema (DME) has been accepted by the Food and Drug Administration, with a targeted Prescription Drug User Fee Act date of August 18, 2014.

The submission was based on positive data from Regeneron’s VIVID and VISTA studies. Eylea is currently approved in the U.S. for neovascular age-related macular degeneration and for macular edema following central retinal vein occlusion.

EyeWorld Weekly Update (1600)

Complications of Glued IOL : Dr Priya Narang

Healio_OSN: BLOG: Complications of glued IOL, by Priya Narang, MS. Read it here: http://ow.ly/rRsOX (912)

17th Annual Conference Of Punjab Ophthalmological Society

AsianOphthalmology Alliance logo 17th Annual Conference Of Punjab Ophthalmological Society to be held at Jalandhar, Punjab, India at Grand Lilly Resorts from Dec 20 to Dec 22 2013. To download the program brochure please click

POS-2013-CONFERENCE BROCHURE .(3.5MB PDF) (857)

Intracameral bevacizumab as an adjunct to trabeculectomy

AsianOphthalmology Alliance logo Intracameral bevacizumab as an adjunct to trabeculectomy

Author(s): Vandewalle E, Abegão Pinto L, Van Bergen T, Spielberg L, Fieuws S, Moons L, Spileers W, Zeyen T, Stalmans I
Treatments discussed: bevacizumab

AIMS To investigate the efficacy and safety of a single intracameral bevacizumab injection to improve the outcome of trabeculectomy.

METHODS A 12-month, prospective, randomised, double-masked, placebo-controlled trial. Patients with medically uncontrolled open-angle glaucoma scheduled for a primary trabeculectomy were recruited and randomised to receive 50 µL of either bevacizumab (1.25 mg) or placebo (balanced salt solution) peroperatively. Absolute success was defined as intraocular pressure (IOP) ≤18 mm Hg and>5 mm Hg with at least 30% reduction from baseline and no loss of light perception. (more…) (798)

Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?

AsianOphthalmology Alliance logo Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?

Author(s): Kiryazov K, Stefova M, Iotova V
Treatments discussed: brimonidine, brinzolamide, timolol

Topical ocular medications have been widely prescribed and successfully used in children for the management of different ophthalmic disorders. We present 2 infants admitted to our pediatric intensive care unit who developed altered state of consciousness, hypotonia, hypothermia, bradycardia, and apnea after instillation of ophthalmic drops. The second infant also had (more…) (1838)

Micro-Stent Safe With Cataract Surgery for Glaucoma

AsianOphthalmology Alliance logo Micro-Stent Safe With Cataract Surgery for Glaucoma

The CyPass Micro-Stent procedure for glaucoma can be safely combined with cataract surgery, according to 2-year results from the CYCLE trial. Investigators report that the procedure provided sustained control of intraocular pressure and reduced medication use.

“This procedure is an attempt to have surgeries for glaucoma that are safer and easier for the patient,” said investigator Brian Flowers, MD, from Fort Worth, Texas. “Current surgical treatments for glaucoma are associated with events such as suprachoroidal hemorrhage and bleb-related complications. Microinvasive surgical stenting of the supraciliary space may improve aqueous flow, with fewer complications,” he explained here at the American Academy of Ophthalmology (AAO) 2013 Annual Meeting.

There are 2 main approaches to minimally invasive glaucoma surgery, (more…) (1282)

Eyedrops Using Novel Compound Restore Corneal Cells

AsianOphthalmology Alliance logo Eyedrops Using Novel Compound Restore Corneal Cells

Rho kinase inhibitor eyedrops stimulate the growth of corneal epithelium, according to a preliminary study in patients with Fuchs dystrophy.

“Think outside the box,” said Shigeru Kinoshita, MD, from Kyoto Prefectural University of Japan. The drops, also known as rock inhibitors, could become a treatment reality in the future. “This is just the beginning,” Dr. Kinoshita said. “We may be heading toward minimally invasive surgery for Fuchs dystrophy and other forms of corneal problems.”

Dr. Kinoshita and his team pioneered the technique as part of research on new therapies for corneal endothelial diseases, as well as for the early stages of Fuchs dystrophy. The first approach is aimed at using cultivated corneal endothelial cells plus a rock inhibitor to promote cell adhesion, proliferation, and inhibition of apoptosis of corneal endothelial cells.

The second effort — to develop a novel medical treatment (more…) (1557)

Oral Contraceptives Linked to Glaucoma

AsianOphthalmology Alliance logo Oral Contraceptives Linked to Glaucoma

Taking oral contraceptives for more than 3 years doubles a woman’s risk for glaucoma, according to a large population-based study.

“This study is the first to document this risk, and it’s important for the general population,” said lead investigator Ye Elaine Wang, MD, from the University of California at San Francisco. “Postmenopausal women should be reassured that the study does not prove causative effects, but women who have used oral contraceptives for 3 years or more and who have additional risk factors for glaucoma should be checked annually for the disease during their eye exams.”

Dr. Wang presented the findings here at the American Academy of Ophthalmology 2013 Annual Meeting.

Known risk factors for glaucoma include age, race, family history of glaucoma, elevated intraocular pressure, and existing visual field defects.

The cross-sectional study was based on 3406 (more…) (653)

NSAIDs Speed Central Serous Choroidopathy Recovery

AsianOphthalmology Alliance logo NSAIDs Speed Central Serous Choroidopathy Recovery

Patients with central serous choroidopathy treated with nonsteroidal anti-inflammatory drug (NSAID) eyedrops recover faster than when they are not treated, according to a new study.

“We found that we could cut the average time to resolution by 50% with the NSAID eyedrops, which is the way we have been treating patients in our own practice,” said Michael Singer, MD, from Medical Center Ophthalmology in San Antonio.

He presented the results here at the American Academy of Ophthalmology 2013 Annual Meeting.

Central serous choroidopathy is characterized by spontaneous serous detachment of the neurosensory retina in the macular region, with or without retinal pigment epithelium detachment. Its cause is not known, but one theory suggests that increased (more…) (1208)

« Previous PageNext Page »